title: Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
abstract: OBJECTIVE
  The common adverse effects associated with targeted therapy for cancer, such as epidermal growth factor receptor inhibitors (EGFRIs), are dermatologic toxicities that cause the patient physical discomfort and affect treatment. Colloidal oatmeal lotion (COL) has been proven to help prevent dermatitis and xerosis. Evidence of its effect on EGFRI-induced dermatologic toxicities, however, is limited. The purpose of this study was to explore the effect of COL on EGFRI-induced dermatologic toxicities.
  
  
  METHODS
  This study used a 1-group pretest-posttest design with a convenience sample of 30 patients with cancer who developed EGFRI-induced dermatologic toxicities from a medical center in southern Taiwan. All participants applied topical COL 3 to 5 times a day for 4 consecutive weeks and received a pretest and 4 posttests.
  
  
  METHODS
  A generalized estimating equation was used to assess the impact of demographics, disease characteristics, and weeks of COL use on dermatologic toxicity severity, body surface area affected, and level of pruritus.
  
  
  RESULTS
  Significant differences were found between the pretest and all posttests after using COL with regard to the severity, body surface area affected, and level of pruritus in participants who developed EGFRI-induced dermatologic toxicities (P < .05). There were no significant differences in demographics or disease characteristics on EGFRI-induced dermatologic toxicities.
  
  
  CONCLUSIONS
  Based on the study results, COL could improve the symptoms of dermatologic toxicities in those receiving EGFRIs with no adverse effects. Therefore, the authors suggest the use of COL in clinical settings.
authors.affiliation: Ya-Ting Ke, RN, is a Head Nurse, Emergency Department, Chi-Mei Medical Center, Tainan, Taiwan; and Doctoral Student, School of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan. Chia-Chi Kuo, RN, is an Advanced Practice Nurse, Emergency Department, Chi-Mei Medical Center, Tainan, Taiwan; and Doctoral Candidate, School of Nursing, Kaohsiung Medical University, Kaohsiung, Taiwan; and Assistant Professor, Department of Nursing, Chang Jung Christian University, Tainan, Taiwan. Acknowledgments: This work was sponsored by grants from the Chi Mei Medical Center, Tainan, Taiwan (CMHCR10110). The authors thank Li-Chien Yang, Kuei-Ching Wang, and Ling-Ling Liang, the head nurses of the Center of Evidence-Based Medicine, Nursing Department, Chi Mei Medical Center, and Chia-Hui Tsai, the Clinical Instructor of the Department of Nursing, Tajen University, Pingtung County, Taiwan, for their dedication to evidence collection and critical appraisal. They also thank attending physicians, Drs Yin-Hsun Feng and Wei-Yu Chen, and the chemotherapy team of the Division of Hematology and Oncology, Chi Mei Medical Center, for their assistance in study recruitment. The authors have disclosed that they have no financial interests related to this article. Submitted December 18, 2014; accepted in revised form August 4, 2015.
authors.forename: Ya-Ting
authors.initials: YT
authors.lastname: Ke
authors.forename: Chia-Chi
authors.initials: CC
authors.lastname: Kuo
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D018554:Avena; D015331:Cohort Studies; D003102:Colloids; D003875:Drug Eruptions / Q000188:drug therapy* / Q000209:etiology; D066246:ErbB Receptors / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008517:Phytotherapy / Q000379:methods*; D010865:Pilot Projects; D010936:Plant Extracts / Q000627:therapeutic use; D012189:Retrospective Studies; D013624:Taiwan; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D003102:Colloids; D010936:Plant Extracts; D066246:ErbB Receptors